Latest news with #FedericoIIUniversity
Daily Mail
3 days ago
- Health
- Daily Mail
I was nearly killed by a broccoli sandwich: Student reveals how she cheated death and describes horrific symptoms as she recovers from deadly snack that has killed two people
A student has revealed that she was nearly killed by a broccoli sandwich that has already killed at least two and left more than a dozen in hospital. Gaia Vitiello, a 24-year-old student at the Federico II University of Naples, was a customer at a food truck in the town of Diamante, in Calabria. After eating a sandwich with broccoli in it at the end of a night out, she was left suffering botulism and needing to be kept in intensive care at a nearby hospital. The languages student said she and her friends all got the same sandwich at 4.30am on August 5, with only one difference: 'My friends only had mayonnaise, sausage, and chips. I added broccoli. It was the first time I'd ever done that'. She told local media that just one hour later, she was suffering: 'I had diarrhea. I thought it was indigestion. The next day, the symptoms worsened. I couldn't swallow and my legs were shaking.' After Gaia's sister took her a nearby clinic, which the student said she didn't want to do, she was immediately transferred to Annunziata Hospital in Cosenza. 'If my sister Alessia hadn't taken me to the hospital by force, I wouldn't be here today', Gaia admitted. Thankfully, she was given the proper medicine and was discharged. She said: 'I consider myself lucky.' Last week, 52-year-old artist Luigi Di Sarno died after eating the panini from a food truck in the town of Diamante, in Calabria. And yesterday, Tamara D'Acunto, 45, also died, and more than a dozen people have been hospitalised. Authorities have launched an investigation into the outbreak and ordered a nationwide recall of the commercially produced panini that has left 14 people with food poisoning including two teenagers. Postmortem examinations are being conducted this week as part of the investigation. The sandwich contained grilled sausages and an Italian summer vegetable called 'cime di rapa' or turnip tops, similar to broccoli. Nine people are being investigated by the authorities, including the owner of the food truck on the seafront in the province of Cosenza whose vehicle as been seized. Three employers of the company who allegedly made the sandwich are also being investigated, as well as five doctors who treated victims near the city of Cosenza. The medics are accused of having not acting quickly enough to save the victims, after Mr Di Sarno's sister alleged that her brother was discharged from hospital despite still feeling sick and later died. Botulism is a rare but life-threatening condition caused by toxins produced by Clostridium botulinum bacteria. The neurotoxins attack the body's nervous system, and can cause respiratory muscle failure, paralysis and death. Di Sarno, an artist and musician originally from Cercola, in the province of Naples, was on holiday in Calabria with his family. After they ate the sandwich on the Tyrrhenian coast of Cosenza, he began driving back home to Naples. But on the way back he fell ill. Others were rushed to Annunziata Hospital in Cosenza, including two 17-year-olds and two women in their 40s. Two of the patients were reportedly in a serious condition when they arrived at the intensive care unit.
Time of India
01-07-2025
- Health
- Time of India
Could Ozempic treat migraines? Popular obesity drug shows promise in a small study
In the world of wellness and weight loss, Ozempic is one heck of a heavyweight name. Ozempic (semaglutide) is a well-known prescription drug that's used to treat the blood sugar of people with type 2 diabetes. Ozempic is given as an injection under your skin, and it is also used to lower the risk of cardiovascular events (heart attack, stroke, or death) in people who have type 2 diabetes and heart disease. But what if a widely used medication for weight management and type 2 diabetes could also ease migraine – a neurological disorder that affects around 15% of people worldwide, and is characterized by debilitating headaches that can be accompanied by nausea, light sensitivity, and fatigue? Ozempic (semaglutide), a GLP-1 receptor agonist, is emerging as a strong contender to provide relief to migraine sufferers. In a small study, the drug liraglutide reduced monthly migraine episodes by nearly half among people with obesity who experience the headache-inducing condition. How? Read on to know. The research: A study led by Simone Braca, a neurologist at Federico II University in Naples, Italy, explored the effects of liraglutide on 31 people suffering from chronic migraines and obesity. All participants had previously tried at least two migraine prevention medications without success. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Giao dịch vàng CFDs với sàn môi giới tin cậy IC Markets Tìm hiểu thêm Undo What is Liraglutide? Liraglutide is a drug made by Novo Nordisk, the same company that produces semaglutide, known as Ozempic for diabetes and Wegovy for weight loss. Both drugs mimic a hormone called GLP-1, which helps control blood sugar and suppress appetite. In this study, liraglutide was tested on the patients for 12 weeks. By the end of the trial, the average number of migraine days each month dropped from about 20 to just under 11 – a nearly 50% reduction. One participant even stopped having migraines entirely. While some individuals lost weight, the reduction in migraines did not appear to be linked to the amount of weight lost, indicating that liraglutide's impact on migraines was separate from its weight-loss effects. The findings: The results of the study were shared in June at the Congress of the European Association of Neurology and published in the journal Headache . The researchers concluded, 'Our findings show that liraglutide may be effective in the treatment of unresponsive high-frequency or chronic migraine in patients with obesity.' GLP-1 drugs have been available for about 20 years, and newer ones like semaglutide and tirzepatide are more successful at helping with weight loss and blood sugar control compared to diet and exercise alone. Additionally, some studies suggest GLP-1s might help people with substance use disorders. Chronic migraines are complicated, but one potential cause is increased pressure inside the skull. Since previous research has shown that GLP-1s can lower this pressure, the researchers believed these drugs could help treat migraines. What is migraine? Migraines are intense headaches often accompanied by nausea and sensitivity to light and sound. They can come with warning signs and be triggered by factors such as hormonal changes, certain foods or drinks, stress, and even exercise. Common symptoms include throbbing pain in one area, nausea, and sensitivity to light (photophobia) and sound (phonophobia). Medications can help manage migraines. The road ahead: The researchers noted this was just a preliminary study and not meant to draw definitive conclusions. Important questions remain, such as whether newer GLP-1 drugs like semaglutide would also effectively relieve migraine-related pressure. Lanfranco Pellesi, a headache specialist from the University of Southern Denmark, who did not participate in the study, pointed out that without a control group, some of the observed reduction in headaches might be due to the placebo effect. However, he mentioned that the findings are promising enough to warrant a randomized controlled trial to further investigate this hypothesis. Given the challenges in treating migraines, discovering new therapeutic options could be extremely valuable. Promising drug delivery method might replace injections with pills: Study
